Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have been given an average recommendation of “Buy” by the eight research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $28.00.

A number of research analysts have weighed in on the company. Cowen reiterated an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Thursday, August 10th. Cantor Fitzgerald assumed coverage on Dynavax Technologies in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 target price on the stock. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Royal Bank Of Canada reiterated a “buy” rating and set a $26.00 target price on shares of Dynavax Technologies in a report on Friday, September 1st. Finally, William Blair reiterated an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Wednesday, August 9th.

Institutional investors and hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC boosted its position in shares of Dynavax Technologies by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Dynavax Technologies by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,700 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Dynavax Technologies by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Dynavax Technologies by 2.3% in the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares in the last quarter. Finally, Wall Street Access Asset Management LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth approximately $124,000. 70.61% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies (NASDAQ:DVAX) opened at $18.40 on Friday. Dynavax Technologies has a twelve month low of $3.70 and a twelve month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the business earned ($0.90) EPS. The business’s revenue for the quarter was down 68.8% on a year-over-year basis. research analysts predict that Dynavax Technologies will post -1.72 EPS for the current year.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/03/dynavax-technologies-corporation-dvax-receives-average-rating-of-buy-from-brokerages.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.